Australia's Paradigm Biopharmaceuticals surges on research partnership deal

Paradigm Biopharmaceuticals

13/07/2022 02:34

** Shares of drug development co Paradigm Biopharmaceuticals
 PAR.AX  jump as much as 7.1% to A$1.125, their highest since
July 6
    ** Co says it has signed partnership agreement for research
about its Osteoarthritis program and potential clinical trial
participation  urn:newsml:reuters.com:*:nFWN2YT3V8
    ** Osteoarthritis occurs when protective cartilage that
cushions the ends of the bones wears down over time
    ** Stock down 44.3% this year, as of last close, vs an
11.3%decrease in the benchmark S&P/ASX 200 index  .AXJO  


 (Reporting by Roushni Nair in Bengaluru)
 ((Roushni.Nair@thomsonreuters.com;))